Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three medications potentially used for treating polycystic ovary syndrome (PCOS), particularly in clomiphene-resistant patients. The combination includes clomiphene citrate (an ovulation inducer), metformin (an insulin-sensitizing agent), and N-acetyl cysteine (a mucolytic agent with antioxidant properties). While studies have compared two-drug combinations (clomiphene+metformin versus clomiphene+N-acetyl cysteine), the provided search results do not contain evidence on using all three medications simultaneously as a single therapeutic approach.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomiphene + metformin + n-acetylcysteine.